Malaria antibody protects infants but lowers immune response to R21 vaccine, trial finds
A single intramuscular dose of an experimental malaria monoclonal antibody safely provided infants with strong protection during Mali's six-month malaria season. However, potential interference with the R21 malaria vaccine is putting plans to pursue development of L9LS for this age group on hold, according to results from a clinical trial presented at the annual meeting of the American Society of…
Read original article on Medical Xpress - latest medical and health news stories →